Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Treatment failure and resistance in Malawi remain subject for debate

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

P Ringwald, medical officer (ringwaldp@who.int)

Roll Back Malaria Department, World Health Organization, 1211 Geneva 27, Switzerland

EDITOR—The methods applied to enhance the interpretation of the data by Plowe et al deserve comment.1

The World Health Organization has developed several standardised protocols to assess the efficacy of antimalarial drugs, which are intended to determine treatment failures and not resistance patterns of the parasite. Recently, WHO published a revised protocol, giving clear indications of outcome classifications and the target groups (children under 5 years …